Post-marketing Safety Study to Assess the Risk of Spontaneous Abortion Following Administration of CERVARIX in the United States and Canada.

Trial Profile

Post-marketing Safety Study to Assess the Risk of Spontaneous Abortion Following Administration of CERVARIX in the United States and Canada.

Discontinued
Phase of Trial: Phase IV

Latest Information Update: 03 May 2013

At a glance

  • Drugs Human papillomavirus vaccine recombinant bivalent Japan Vaccine/MedImmune (Primary)
  • Indications Cervical cancer; Human papillomavirus infections
  • Focus Adverse reactions
  • Sponsors GlaxoSmithKline
  • Most Recent Events

    • 06 Oct 2011 Status changed from not yet recruiting to recruiting as reported by ClinicalTrials.gov.
    • 11 Aug 2011 Planned initiation date changed from 1 Jul 2011 to 1 Sep 2011 as reported by ClinicalTrials.gov.
    • 11 Aug 2011 Status changed from active, no longer recruiting to not yet recruiting as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top